Show simple item record

dc.contributor.authorJiménez Luna, Cristina
dc.contributor.authorMartin Blázquez, Ariadna
dc.contributor.authorDiéguez Castillo, Carmelo
dc.contributor.authorDíaz, Caridad
dc.contributor.authorMartín Ruiz, José Luis 
dc.contributor.authorGenilloud, Olga
dc.date.accessioned2021-01-25T10:25:01Z
dc.date.available2021-01-25T10:25:01Z
dc.date.issued2020-10-22
dc.identifier.citationJimenez-Luna, C., Martin-Blazquez, A., Dieguez-Castillo, C., Diaz, C., Martin-Ruiz, J. L., Genilloud, O., ... & Caba, O. (2020). Novel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomics. Metabolites, 10(11), 423. [doi:10.3390/metabo10110423]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/65971
dc.description.abstractPancreatogenic diabetes mellitus (T3cDM) is a highly frequent complication of pancreatic disease, especially chronic pancreatitis, and it is often misdiagnosed as type 2 diabetes mellitus (T2DM). A correct diagnosis allows the appropriate treatment of these patients, improving their quality of life, and various technologies have been employed over recent years to search for specific biomarkers of each disease. The main aim of this metabolomic project was to find di erential metabolites between T3cDM and T2DM. Reverse-phase liquid chromatography coupled to high-resolution mass spectrometry was performed in serum samples from patients with T3cDM and T2DM. Multivariate Principal Component and Partial Least Squares-Discriminant analyses were employed to evaluate between-group variations. Univariate and multivariate analyses were used to identify potential candidates and the area under the receiver-operating characteristic (ROC) curve was calculated to evaluate their diagnostic value. A panel of five di erential metabolites obtained an area under the ROC curve of 0.946. In this study, we demonstrate the usefulness of untargeted metabolomics for the di erential diagnosis between T3cDM and T2DM and propose a panel of five metabolites that appear altered in the comparison between patients with these diseases.es_ES
dc.description.sponsorshipJunta de Andalucía PIN-0474-2016 PC-0549-2017 PC-0498-2017
dc.description.sponsorshipInstituto de Salud Carlos III DTS17/00081
dc.description.sponsorshipFundación MEDINA, a public-private partnership of Merck Sharp and Dohme de España S.A./Universidad de Granada/Junta de Andalucía PIN-0474-2016
dc.language.isoenges_ES
dc.publisherMdpies_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectMetabolomicses_ES
dc.subjectUntargeted LC-HRMSes_ES
dc.subjectDiagnosis es_ES
dc.subjectPancreatogenic diabetes mellituses_ES
dc.subjectType 2 Diabetes Mellituses_ES
dc.subjectChronic pancreatitises_ES
dc.subjectBiomarkerses_ES
dc.titleNovel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomicses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/metabo10110423
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España